Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yingying, Jia, Ran, Shao, Yang W., Zhu, Liuqing, Ou, Qiuxiang, Yu, Man, Wu, Xue, Zhang, Yanbei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411253/
https://www.ncbi.nlm.nih.gov/pubmed/32850382
http://dx.doi.org/10.3389/fonc.2020.01259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411253/
https://www.ncbi.nlm.nih.gov/pubmed/32850382
http://dx.doi.org/10.3389/fonc.2020.01259

Ejemplares similares